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The use of dopamine replacement therapies (DRT) in the treatment of Parkinson’s
disease (PD) can lead to the development of dopamine dysregulation syndrome
(DDS) and impulse control disorders (ICD), behavioral disturbances characterized by
compulsive DRT self-medication and development of impulsive behaviors. However, the
mechanisms behind these disturbances are poorly understood. In animal models of PD,
the assessment of the rewarding properties of levodopa (LD), one of the most common
drugs used in PD, has produced conflicting results, and its ability to promote increased
impulsivity is still understudied. Moreover, it is unclear whether acute and chronic LD
therapy differently affects reward and impulsivity. In this study we aimed at assessing, in
an animal model of PD with bilateral mesostriatal and mesocorticolimbic degeneration,
the behavioral effects of LD therapy regarding reward and impulsivity. Animals with
either sham or 6-hydroxydopamine (6-OHDA)-induced bilateral lesions in the substantia
nigra pars compacta (SNc) and ventral tegmental area (VTA) were exposed to acute
and chronic LD treatment. We used the conditioned place preference (CPP) paradigm
to evaluate the rewarding effects of LD, whereas impulsive behavior was measured
with the variable delay-to-signal (VDS) task. Correlation analyses between behavioral
measurements of reward or impulsivity and lesion extent in SNc/VTA were performed
to pinpoint possible anatomical links of LD-induced behavioral changes. We show that
LD, particularly when administered chronically, caused the development of impulsive-like
behaviors in 6-OHDA-lesioned animals in the VDS. However, neither acute or chronic
LD administration had rewarding effects in 6-OHDA-lesioned animals in the CPP. Our
results show that in a bilateral rat model of PD, LD leads to the development of impulsive
behaviors, strengthening the association between DRT and DDS/ICD in PD.
Keywords: Parkinson’s disease, dopamine dysregulation syndrome, impulse control disorders, 6-OHDA,
levodopa
INTRODUCTION
Parkinson’s disease (PD) is a chronic neurodegenerative disorder affecting the dopaminergic
system, causing significant neuronal loss in the substantia nigra pars compacta (SNc, or
A9), and in the ventral tegmental area (VTA, or A10; Hirsch et al., 1988; German et al.,
1989; Parkinson, 2002), and characterized by a number of different motor and non-motor
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symptoms (Jankovic, 2008; Obeso et al., 2008; Chaudhuri and
Schapira, 2009; Dirnberger and Jahanshahi, 2013). Dopamine
replacement therapies (DRT), namely levodopa (LD) and
dopamine agonists (DAg), can significantly ameliorate motor
and non-motor symptoms of PD (Maricle et al., 1995; Antonini
et al., 2009; Hauser, 2009; Seppi et al., 2011). However, in some
patients, chronic DRT leads to the emergence of addictive
and/or impulsive behaviors. Abuse of DRT, particularly LD, a
condition known as dopamine dysregulation syndrome (DDS),
is characterized, among other symptoms, by the development
of compulsive self-medication behaviors (Giovannoni et al.,
2000; Pezzella et al., 2005). In turn, impulse control disorders
(ICD), mainly associated with DAg, are characterized by
the development of several ‘‘behavioral addictions’’ (Potenza
et al., 2007), namely pathological gambling, hypersexuality
and eating and buying/shopping compulsions (Molina et al.,
2000; Klos et al., 2005; Pezzella et al., 2005; Weintraub et al.,
2010). The particular association between each set of behavioral
disturbances and a class of DRT could suggest independent
mechanisms underlying DDS and ICD, however this is not fully
understood, as there is evidence supporting a role for LD in
increasing the risk of ICD when combined to DAg, compared to
DAgmonotherapy (Weintraub et al., 2010). Regardless of the fact
that the causal mechanisms for DDS and ICD are unknown, it is
interesting to observe that they share many behavioral features,
including a compulsive pattern of DRT abuse (for DDS) and
engagement in ‘‘behavioral addictions’’ (for ICD; Giovannoni
et al., 2000; Voon et al., 2017), the hedonic value that DRT
abuse and ‘‘behavioral addictions’’ can hold (Giovannoni et al.,
2000; Evans et al., 2009); and the development of withdrawal
symptoms if LD or DAg dosages are reduced, or if engagement
in ‘‘behavioral addiction’’ is restricted (Giovannoni et al., 2000;
Evans et al., 2009; Pondal et al., 2013). Remarkably, both of
these syndromes also share behavioral and functional similarities
with substance addictions or impulsive behaviors in healthy
individuals (Voon and Fox, 2007; Dagher and Robbins, 2009).
Based on this, and in accordance with a theory of dopamine
(DA) ‘‘overdose’’, DDS and ICD in PD have been linked to
an excessive dopaminergic stimulation of the relatively spared
mesocorticolimbic pathway caused by DRT (Dagher and
Robbins, 2009; O’Sullivan et al., 2009; Voon et al., 2017). Indeed,
in the course of PD, the mesocorticolimbic pathway, originating
in the VTA (area A10) is less affected than the mesostriatal
pathway (German et al., 1989), and several reports have shown
a causal link between the specific activation of this pathway and
reward-seeking behaviors (Tsai et al., 2009; Pascoli et al., 2015).
Such overstimulation is believed to cause oversensitization of
brain reward circuits, leading to a heighten reward salience in
PD patients, together with insensitivity to negative outcomes
(Dagher and Robbins, 2009; O’Sullivan et al., 2009; Voon et al.,
2017). Simultaneously, a disruption of cognitive inhibitory
networks can impair impulse control (O’Sullivan et al., 2009;
Voon et al., 2017). Support for this hypothesis is found in human
studies showing that in PD patients, DRT can significantly impair
reward-based learning, making patients overvalue positive
rewards while desensitizing them to risk or negative outcomes
(Bódi et al., 2009; Housden et al., 2010; Voon et al., 2010a, 2011),
and foster impulsive responding (Housden et al., 2010; Voon
et al., 2010b).
Few studies have tried replicating features of DDS/ICD
in animal models of PD, and indeed they are essential
for understanding the impact of DRT upon parkinsonian
dopaminergic networks and how they may lead to the
development of DDS/ICD (Cenci et al., 2015). However, some
studies have shown the rewarding effects of specific DAg in
rodent models of PD, measured with the conditioned place
preference (CPP) paradigm (Riddle et al., 2012; Ouachikh
et al., 2013, 2014; Zengin-Toktas et al., 2013). DAg, specifically
pramipexole, was also found to cause, in models of PD, impulsive
behaviors in a probability-discounting task (Rokosik and Napier,
2012), but also waiting and motor impulsivity (Engeln et al.,
2016). In the case of LD, it was also shown that it can have
rewarding properties in SNc-lesioned rats (Engeln et al., 2013b),
though this finding was inconsistent with another study, which
found no effect in animals with bilateral mesostriatal and
mesocorticolimbic degeneration (Zengin-Toktas et al., 2013).
Evidence of the effects of LD upon measures of impulsive
behavior has been more limited, although a recent study
described no effects of LD in both motor and waiting impulsivity
in animals with SNc dopaminergic lesions (Engeln et al., 2016).
Additionally, it is still poorly understood how the chronic effects
of LD, in contrast to its acute effects, may differently affect
PD dopaminergic pathways and lead to the development of
DDS/ICD-like behaviors.
To further address the rewarding effects of different regimes
of LD treatment but also their impact upon measures of
impulsive behavior, we have used an animal model of PD with
bilateral 6-hydroxydopamine (6-OHDA) SNc/VTA (A9/A10)
lesions, mimicking the degenerative profile of human PD. We
evaluated the potential of both acute and chronic administration
of LD to cause the emergence of impulsive behaviors, expressed
as premature responding in a variable delay-to-signal task (VDS;
Leite-Almeida et al., 2013). Moreover, we employed the CPP
paradigm to assess the rewarding nature of acute or chronic
LD treatments in our model. Finally, we performed individual
anatomical analyses of lesion extent to identify correlates of these
behaviors, which may be important for the comprehension of the
pathophysiology of DDS/ICD in human PD.
MATERIALS AND METHODS
Animals and 6-OHDA Lesions
Wistar-Han male rats (Charles River, Barcelona), 11 weeks old
were housed, two per cage, under standard laboratory conditions:
12 h light–dark cycle, 22◦C room temperature, 55% relative
humidity, food and water available ad libitum. When required,
food availability was restricted to 1 h/day (19.00–20.00), with
weight regularly monitored to prevent losses 15% below of initial
weight. Behavioral assessment was performed between 09.00 AM
and 16.00 PM, during the light part of the cycle. Previous
consent was obtained from the Portuguese national authority
for animal experimentation, Direção-Geral de Alimentação e
Veterinária. Animals were kept and handled in accordance with
the guidelines for the care and handling of laboratory animals in
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FIGURE 1 | Graphic representation of the experimental design. Staircase—Forelimb skilled motor function. VDS, Variable delay-to-signal—Impulsive responding. All
sham and 6-OHDA animals performed the task in both behavioral assessment phases. CPP, Conditioned Place Preference—Positive reinforcement. For CPP, sham
and 6-OHDA groups were divided in two subgroups, one performing the task in the acute phase and the other on the chronic phase. This was done to avoid
possible conditioning memories created during the acute phase from biasing conditioned responses in the chronic phase.
the Directive 2010/63/EU of the European Parliament and of the
Council.
6-OHDA lesions were performed under ketamine-
medetomidine anesthesia (75 mg/Kg: 0.5 mg/Kg, i.p.). Thirty
minutes before 6-OHDA injections the animals were treated with
desipramine hydrochloride (Sigma, San Antonio, TX, USA),
15 mg/Kg, i.p., to avoid uptake of 6-OHDA by noradrenergic
neurons. Bilateral sham (sham group, n = 31) or 6-OHDA
hydrochloride (Sigma; 6-OHDA group, n = 33) lesions were
made in both SNc and VTA. SNc and VTA coordinates related
to Bregma and according to Paxinos and Watson (1998): SNc:
AP = −5.2 mm; ML= ± 2.2 mm; DV = −7.7 mm. VTA:
AP = −5.2 mm; ML= ± 0.8 mm; DV = −8.2 mm. The incisor
bar was set at−3.3 mm. Sham animals received 2 µl of 0.2 µg/µl
ascorbic acid in 0.9% NaCl. 6-OHDA animals received 2 µl of
1.0 µg/µl 6-OHDA hydrochloride with 0.2 µg/µl ascorbic acid
in 0.9% NaCl. All injections were performed with a 0.5 µl/min
flow, and the needle was left in place for 4 min after each of the
four injections.
Experimental Design
The experimental protocol (Figure 1) was initiated 3 weeks
post-surgery. After an initial assessment of motor function
with the staircase test, the protocol continued with two blocks
of behavioral assessment. In the first block (acute phase) we
assessed the effects of an acute LD treatment in the development
of impulsive behavior using the VDS task, and of LD reward
using the CPP. We then initiated chronic LD treatment to all
the animals enrolled in the study (sham and 6-OHDA), and after
1 week of treatment motor function was reassessed. After 2 weeks
of chronic LD treatment we performed the second block of
behavioral assessment (chronic phase), using the same tasks as in
the first block. Chronic LD treatment was continued throughout
the second block of behavioral assessment and until the end of
the study.
LD Treatment
Sham and 6-OHDA animals were exposed to both acute
and chronic LD according to the experimental design
(Figure 1). For acute LD treatment, Sinemetr tablets (Sinemetr,
100/25 levodopa/carbidopa, Merck, Sharp and Dohme, S.p.A,
Italy) were crushed in water and given by oral gavage, 12 mg/Kg,
1 h before behavioral assessment. Oral gavage was chosen as
route of administration to more closely replicate the human
therapeutic setting. Treatment doses were based on the
therapeutic range of LD reported for a unilateral lesion model of
PD (Lindner et al., 1996), but adjusted to avoid severe dyskinesias
in our model with bilateral dopaminergic degeneration. During
chronic LD treatment both sham and 6-OHDA animals received
oral LD, 12 mg/Kg, twice daily, one dose between 08.00 AM and
12.00 AM and another between 16.00 PM and 20.00 PM, until the
end of the study. In the second block of behavioral assessment
the animals also performed the tests ‘‘ON’’ LD, receiving the
morning treatment 1 h before behavioral assessment.
Behavioral Assessment
Staircase Test
To assess skilled forelimb motor function, we performed the
staircase test (Model 80300, Campden Instruments, UK; Klein
and Dunnett, 2012). Before 6-OHDA lesions, food-deprived
animals were presented with the food pellets in their home cage
and trained in one daily session for five consecutive days. On
day 1 the animals were habituated for 5 min to the box. On day
2 the animals were placed 10 min in the box and presented with
pellets on each side of the stair and along the central plinth. From
days 3 to 5 the animals were placed in the box for 15 min with
food pellets present only on the staircases. Staircase testing was
performed in food-deprived animals during seven consecutive
days, with a daily 15 min session. During each session forelimb
function was measured as success rate, i.e., percentage of total
pellets successfully retrieved, and results were plotted for each
group and each testing day. Testing sessions were conducted
after lesion, to assess the effect of 6-OHDA injections in motor
function, and a randomly selected sample of sham and 6-OHDA
animals was retested after 1 week of chronic LD treatment
(Figure 1), to determine the therapeutic efficacy of the LD doses
used in the study. This retest was performed ‘‘ON’’ LD, 1 h after
treatment administration. Importantly, after LD administration
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some 6-OHDA animals (n = 5) developed noticeable forelimb
dyskinesias in the form of involuntary motor jerks and were
incapable of accomplishing the staircase task. To avoid this bias
on the general efficacy of LD to improve motor function, both
pre and post-treatment data of these animals was removed.
Variable Delay-to-Signal
To assess impulsive behavior we performed the VDS task (Leite-
Almeida et al., 2013). Animals were kept food-deprived during
the whole protocol, which included habituation, training and
testing phases. The protocol was performed in a nearly square
shaped (25 × 25 cm) 5-hole operant chamber (OC; TSE Systems
GmbH, Germany). Five square apertures (2.5 × 2.5 cm; #1–#5)
equipped with a 3W light bulb and infrared photobeams to detect
movements were distributed in a slightly curved wall. On the
opposite wall there was another aperture (#6), also equipped
with light and photobeams, connected to a food dispenser.
Above aperture #6 a houselight illuminated the OC. OCs were
placed inside a sound-attenuating chamber, with electrical fans
providing ventilation and white noise.
Habituation phase took place in two consecutive days, each
with two daily sessions with a 5 h interval. On the first two
sessions the animals were placed inside the boxes for 15 min,
in darkness, and presented with food pellets (45 mg; BioServ
Inc., Flemington, NJ, USA) in aperture #6; apertures #1–#5 were
blocked with ametallic cap. On sessions 3 and 4, the animals were
placed for 30 min inside the box, with lights #3, #6 and house-
light turned on. Food pellets were freely available on #3 and #6
(apertures #1, #2, #4 and #5 were blocked in this and in the
upcoming training and testing sessions). The training sessions
started the next day and were performed once a day. Each
training session started with the delivery of a food pellet. Pellet
collection in #6 triggered a 3 s intertrial interval (ITI)—delay
period—that was followed by a response period in which #3 light
was on. Nosepokes in aperture #3 within 60 s were rewarded
with a food pellet and a new ITI occurred. Responses in the
delay period—premature responses—were punished with the
houselight turning off (5 s) and absence of reward. Training
sessions were carried until 100 trials were completed or until
30 min had elapsed, on several consecutive days until average
premature responding stabilized. Training sessions lasted 11 days
in the acute phase and four in the chronic phase. Animals failing
to complete 100 trials in the 30 min limit at the end of the
training period were removed from the task. At the end of the
training period animals were exposed to the single VDS testing
day, during which the animals were subjected to 25 initial trials
with a 3 s delay period, followed by 70 trials of randomly selected
6 s or 12 s delay periods. In the testing day, premature responses,
executed before the delay period had elapsed and #3 light was
turned on, were not punished and were recorded as a measure
of impulsivity. Both sham and 6-OHDA animals were exposed
to the complete task, on both behavioral assessment phases
(Figure 1). In the acute phase, training was performed without
any treatment and on the testing day the animals in each group
were randomly treated with either LD or vehicle, 1 h before
starting the test. In the chronic phase, training sessions were
performed ‘‘OFF’’ LD, with the animals receiving their daily LD
treatment only after ending that day’s training session. In the
testing day the animals received the same treatment as in the
acute phase, 1 h before starting the test.
Conditioned Place Preference
After the end of the VDS task animals were returned to an
ad libitum food regime. The rewarding nature of LD was assessed
with the CPP paradigm during eight consecutive days. The
apparatus consisted of a central gray box, connected on each
side by a lateral door to two boxes, distinct in both color
(black/white) and floor texture (grid/wire mesh; MED-CPP-013,
Med Associates, Inc., St. Albans City, VT, USA). On day 1 the
animals were placed for 5 min in the gray box for habituation,
after which the lateral doors were opened, allowing the animals
to freely explore both the white and the black box for 15 min.
The box where the animal spent more time was considered
the preferred one. On days 2–7 the animals were conditioned,
based on their initial preference. On days 2, 4 and 6 the animals
received water, orally, 1 h before being placed in the preferred
box for 20 min. On days 3, 5 and 7 the animals received LD,
orally, 1 h before being placed in the non-preferred box for
20 min. On day 8, after 5 min habituation in the gray box the
animals were allowed to freely explore all the boxes. Reward-
seeking behavior was assessed by comparing time spent in the
assigned LD box during pre-conditioning and post-conditioning
stages of the task. Due to the persistence of possible conditioned
memories between the two behavioral assessment phases we
divided our experimental groups in two. One group of both sham
and 6-OHDA animals were exposed to the CPP in the acute phase
and the other group was used in the chronic phase (Figure 1).
TH Immunohistochemistry and TH+ Cell
Counts
At the end of the experimental protocol animals were deeply
anesthetized with sodium pentobarbital and transcardially
perfused with ice-cold 0.9% NaCl. The animals were decapitated
and the heads were immersed in liquid nitrogen for 10 s. The
brains were removed and cut into two blocks. The anterior
block was used for macrodissection of the dorsal striatum
(dSTR) and nucleus accumbens (NAcc). The samples were stored
at −80◦C until being processed for high performance liquid
chromatography (HPLC) measurements of DA concentrations.
The posterior block, containing the ventral mesencephalon, was
post fixed in 4% PFA for 3 days (room temperature) and then
stored in 8% sucrose (4◦C) until further use. Five series of coronal
sections of the mesencephalon, 30 µm thick, were obtained
using a vibratome (VT1000S, Leica, Germany), and one series
was used for tyrosine hydroxylase (TH) immunohistochemistry.
Briefly, inhibition of endogenous peroxidase was performed by
immersing the slices in 1× PBS with 3% H2O2 for 20 min.
Slices were then blocked with 5% fetal calf serum in 1× PBS
for 2 h and incubated over-night at 4◦C with rabbit anti-rat
TH primary antibody (Millipore, Billerica, MA, USA, 1:2000 in
2% fetal calf serum in 1× PBS-T). The slices were then
incubated 30 min with a biotinylated secondary anti-rabbit
antibody (LabVision, Fremont, CA, USA) then 30 min with
an Avidine/Biotine complex (LabVision). Antigen visualization
Frontiers in Behavioral Neuroscience | www.frontiersin.org 4 August 2017 | Volume 11 | Article 145
Carvalho et al. Levodopa Affects Reward and Impulsivity
was performed with 3,3í-diaminobenzidine tetrahydrochloride
(DAB, Sigma; 25 mg DAB in 50 ml Tris–HCl 0.05M, pH 7.6 with
12.5 µl H2O2).
Quantification of lesion extent was made by TH+ cell counts.
Five identical TH-labeled slices, along the anterior-posterior
axis of the mesencephalon and containing both the A9 and
A10, were selected per animal based on anatomical references
(Figure 2). With a bright-field microscope (BX51, Olympus,
USA), equipped with a digital camera (PixeLINK PL-A622,
CANIMPEX Enterprises Ltd., Halifax, NS, Canada), we used
VisiomorphTM (V2.12.3.0, Visiopharm, Denmark) software to
draw the boundaries of areas A9 and A10 (Paxinos and Watson,
1998). Area A9 comprised all regions of SNc, while A10 area
included the VTA, parabrachial nucleus, paranigral nucleus,
rostral and caudal linear nuclei and interfascicular nucleus, as
previously described (Rodríguez et al., 2001; Bentivoglio and
Morelli, 2005). All A9 and A10 TH+ cells were counted in both
hemispheres for each of the five slices of sham and 6-OHDA
animals and summed for each area, per animal. Lesion extent in
A9 and A10 for each 6-OHDA animal is expressed as % of total
TH+ cells lost in each area, compared to the average total of TH+
cells in sham animals.
High Performance Liquid Chromatography
DA tissue levels in dSTR and NAcc were measured using reverse
phase ion pairing high performance liquid chromatography with
electrochemical detection (HPLC-ED) as previously described
(Kyratsas et al., 2013; Novais et al., 2013) with minor
modifications. Specifically, samples were weighed, homogenized
and deproteinized in 0.1 N perchloric acid solution (Applichem,
Darmstadt, Germany) containing 7.9 mM Na2S2O5 and
1.3 mM Na2EDTA (Riedel-de Haën AG, Seelze, Germany), then
centrifuged at 4◦C for 45 min at 20,000 g and the supernatant
was stored at −80◦C until analysis. The mobile phase consisted
of a 50 mM phosphate buffer at pH 3.0, with 300 mg/L
5-octylsulfate sodium salt as the ion pairing reagent, 20 mg/L
Na2EDTA (Riedel-de Haën AG) and 8%–12% v/v acetonitrile
(Merck, Darmstadt, Germany) The working electrode of the
electrochemical detector was set at +800 mV. The column used
was an Aquasil C18 HPLC Column, 250 mm × 4.6 mm, 5 µm
Particle Size (Thermo Electron, UK). As previously (Bessinis
et al., 2013; Melo et al., 2015), the quantification of DA was
done by comparing the area under the curve against known
external reference standards using appropriate HPLC software
(Clarity v.7 DataApex, Prague, Czech Republic). The detection
FIGURE 2 | Histological and neurochemical characterization of lesion extent. (A) Representative photomicrographs of the five tyrosine hydroxylase (TH)-labeled
slices selected along the anterior-posterior axis for histological characterization of lesion extent. Scale bar = 2 mm. (B) Quantification of the total number of TH+ cells
counted bilaterally in A9 and A10 on the five selected slices of both sham (black bars, n = 10) and 6-OHDA animals (gray bars, n = 31). (C) Quantification of the
number of TH+ cells in each hemisphere of both A9 and A10 in 6-OHDA animals (n = 31). (D) Representation of 6-OHDA lesion variability in A9 and A10 regions
(n = 31). (E) Measurement of DA content in the dorsal straitum (dSTR, sham: black bars, n = 31; 6-OHDA: gray bars, n = 29) and nucleus accumbens (NAcc sham:
black bars, n = 31; 6-OHDA: gray bars, n = 31). Data presented as mean ± SEM. ∗∗∗p < 0.0001.
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limit was 1 pg/20 ul of sample volume and results are expressed
as microgram of DA per gram of wet tissue.
Statistical Analysis
All data presented as mean± SEM and analyzed using GraphPad
Prismr 5.0b (GraphPad Software Inc., San Diego, CA, USA)
and IBMr SPSSr Statistics 22 (IBM Corporation, Armonk,
NY, USA). Histological neurochemical and CPP data were
analyzed with Student’s T test. The results of the staircase and
VDS tests were performed using mixed-design ANOVA and
Kruskal-Wallis test, followed by Dunn’s post hoc test. Analyses of
correlation between degree of lesion and measures of impulsive
responding and degree of CPP conditioning were performedwith
the Pearson’s test. Statistical significance set at p< 0.05.
RESULTS
Histological and Neurochemical Lesion
Characterization
Histological analysis of brain slices showed that 6-OHDA
animals displayed a marked anterior-posterior reduction in TH
staining in A9 and A10 on both hemispheres (Figure 2A).
Quantitatively, 6-OHDA injections caused a significant loss of
∼70% of TH+ cells in area A9 (t = 10.24, p < 0.0001), and
of ∼32% in area A10 (t = 6.698, p < 0.0001; Figure 2B),
with no differences in lesion extent between hemispheres in
either brain area (Figure 2C; t = 1.452, p = 0.1517 for A9,
t = 1.046, p = 0.2998 for A10). Importantly, 6-OHDA lesions
showed some degree of variability, ranging from 36% to 99%
in the SNc and from 14% to 73% in the VTA (Figure 2D). To
further characterize the dopaminergic degeneration induced by
6-OHDA lesions, we performed HPLC measurements of DA
content in the major projection targets of A9 and A10 DA
neurons—dSTR and nucleus NAcc (Figure 2E). Consistent with
the dopaminergic lesions induced in A9 and A10, 6-OHDA
animals presented significant decreases of DA content in both
areas, compared to sham animals (dSTR: t = 11.030, p < 0.0001;
NAcc: t = 9.252, p< 0.0001).
Assessment of Motor Function and Effect
of LD Therapy
In the staircase test (Figure 3) repeated-measures analysis
showed that performance was significantly affected by
session (F(1,57) = 8.616, p = 0.005), indicating an overall
improvement of success rate with repeated sessions (Figure 3A).
Importantly, 6-OHDA-lesioned animals developed severe motor
impairments in forelimb function compared to sham animals
(F(6,342) = 13.897, p < 0.001; Figure 3A). There was no effect
of the interaction between these two factors (F(6,342) = 0.545,
p = 0.774).
One week after initiating LD treatment we retested a
subset of both 6-OHDA and sham animals, 1 h after the
morning dose of LD, to evaluate the therapeutic relevance
of the LD treatment used in our study (Figure 3B). In
this subset of animals, we confirmed that in the post-lesion
period motor performance was significantly affected by session
FIGURE 3 | Effect of 6-OHDA lesions and levodopa (LD) treatment on skilled
forelimb motor function. (A) Longitudinal post-lesion assessment of staircase.
6-OHDA, n = 30; sham, n = 28. (B) Reassessment of motor performance
during LD treatment in a subset of 6-OHDA (n = 11) and sham (n = 20)
animals tested in (A). Data presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01.
(F(6,174) = 15.281, p < 0.0001), with 6-OHDA-lesioned animals
displaying a significantly lower success rate in retrieving food
pellets (F(1,29) = 4.356, p = 0.046), and no interaction between the
factors (F(6,174) = 0.7205, p = 0.634).With treatment, we observed
no significant differences in motor performance between sham
and 6-OHDA animals (F(1,29) = 3.361, p = 0.077). Session
(F(6,174) = 1.110, p = 0.359) and the interaction between the
factors were also not significant (F(6,174) = 1.070, p = 0.382).
Effect of Acute and Chronic LD Treatment
on Premature Responses in the VDS
Acute Phase
In the training phase of VDS task (Figure 4) both sham and
6-OHDA groups acquired a stable performance (Figure 4A).
Repeated-measures analysis showed a significant within-group
effect of session day in the number of premature responses
(F(10,580) = 40.796, p < 0.0001). Curiously, the analysis of
between-group effects showed that in the overall analysis sham
rats displayed a higher % of trials prematurely interrupted than
6-OHDA-lesioned (F(1,58) = 3.990, p = 0.05). There was no
effect of the interaction between the factors (F(10,580) = 0.732,
p = 0.695). On the VDS test session (Figure 4B), our analysis
showed a significant effect of delay (F(2,92) = 281.631, p< 0.0001)
and treatment (F(1,46) = 9.757, p = 0.003) on the number
of premature responses as well as an interaction between the
factors (F(2,92) = 7.855, p = 0.001), i.e., LD-treated groups
displayed decreased tolerance to delay. Premature responses
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FIGURE 4 | Effect of acute and chronic LD treatments in premature responding in the VDS. (A) Behavior performance in the training phase of the VDS protocol for
both 6-OHDA (n = 28) and sham (n = 31). (B) Comparison of premature responding between sham and 6-OHDA animals acutely treated with LD (sham + LD,
n = 15; 6-OHDA + LD, n = 13), and their respective vehicle controls (sham + vehicle, n = 8; 6-OHDA + vehicle, n = 13) for each type of delay trials. Inset indicates
average latency to feed for all groups during test. (C) Effects of chronic LD treatments on premature responding on sham and 6-OHDA treated with LD (sham + LD,
n = 15; 6-OHDA + LD, n = 14); and their respective vehicle controls (sham + vehicle, n = 13; 6-OHDA + vehicle, n = 13). Inset indicates average latency to feed for all
groups during test. (D) Comparison between premature responding in acute and chronic phases of testing (sham + LD, n = 15; sham + vehicle, n = 8; 6-OHDA +
LD, n = 13; 6-OHDA + vehicle, n = 13). Data presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01.
were not significantly affected by lesion (F(1,46) = 0.982,
p = 0.327), and there were no lesion × delay (F(2,92) = 1.766,
p = 0.177), lesion × treatment (F(1,46) = 0.693, p = 0.409),
or delay × lesion × treatment (F(2,92) = 0.500, p = 0.608)
interactions. Pairwise comparisons between each LD group and
their respective vehicle controls showed that only in the 12 s
delay the acute LD treatment caused a significant increase in the
number of premature responses in the sham group (p < 0.05)
and a marginal increase in 6-OHDA animals (p = 0.08).
Additionally, we observed no significant effects of LD treatment
onmotor behavior, measured with the latency to feed (H = 1.603,
p = 0.659), with post hoc pairwise comparisons showing no
significant differences between groups (p > 0.05; Figure 4B,
inset).
Chronic Phase
In the training sessions of the VDS during the chronic phase
(Figure 4A) both experimental groups presented a similar
stable performance, with no significant effects of session day
(F(3,174) = 0.430, p = 0.732), lesion (F(1,58) = 0.300, p = 0.586),
or the interaction of the two factors (F(3,174) = 0.666, p = 0.574).
Data analysis of the VDS (Figure 4C) revealed that delay
(F(2,102) = 219.283, p < 0.0001) and delay × treatment
(F(2,102) = 5.241, p = 0.007) had again a significant effect
on premature responding. In contrast, premature responses
were not significantly affected by lesion (F(1,51) = 0.265,
p = 0.609), treatment (F(1,51) = 2.920, p = 0.094), delay × lesion
(F(2,102) = 0.247, p = 0.782), lesion × treatment (F(1,51) = 0.833,
p = 0.366) or delay × lesion × treatment (F(2,102) = 0.505,
p = 0.605). Pairwise comparisons for each of the delays showed
that chronic LD intake only caused a significant increase in the
number of premature responses in 6-OHDA animals during the
12 s delay (p < 0.05). Again, we observed no significant effects
of LD treatment on latency to feed (H = 6.266, p = 0.099),
with no significant differences in post hoc pairwise comparisons
(p > 0.05; Figure 4C, inset). To further investigate the chronic
effects of LD treatment we next compared the chronic phase to
the acute phase performance for each of the groups (Figure 4D).
This analysis showed that, for the larger delay, chronic exposure
to LD increased, but not significantly (p > 0.05), the number of
premature responses in all groups, except in 6-OHDA-lesioned
animals treated with vehicle.
Rewarding Effects of Acute and Chronic
LD Treatment in the CPP
Acute Phase
Our results from the CPP test (Figure 5) showed that in response
to an acute exposure to LD, animals with 6-OHDA lesions
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FIGURE 5 | Assessment of positive reinforcement of acute and chronic LD treatments with the CPP. (A) Time spent in the LD-paired box during pre and post
conditioning stages of the CPP for both sham (n = 15) and 6-OHDA-lesioned animals (n = 17), after acute LD treatment. (B) Time spent in the LD-paired box during
pre and post conditioning stages of the CPP for both sham (n = 16) and 6-OHDA-lesioned animals (n = 16), after exposure to a period of chronic LD. Data presented
as mean ± SEM.
had no significant increase in the time spent in the LD-paired
compartment (t = 0.472, p = 0.643; Figure 5A). Similarly,
LD treatment had no significant effect in the time spent by
sham-lesioned animals in the LD box (t = 0.864, p = 0.402).
Chronic Phase
After a period of 2 weeks of chronic LD treatment a second group
of both sham and 6-OHDA-lesioned animals were exposed to
the CPP protocol (Figure 5B). Again, we observed that LD did
not cause any significant changes in the time that either sham
(t = 1.239, p = 0.234) or 6-OHDA-lesioned (t = 1.226, p = 0.239)
animals spent in the LD-paired box.
Correlations between Lesion Extent and
Behavior Measures
Taking advantage of the observed variability in the individual
extent of dopaminergic lesions in 6-OHDA animals, we
analyzed potential associations between lesion severity and
LD-induced phenotypes in both VDS and CPP tasks. We
observed a significant negative association between the number
of premature responses of the 6-OHDA + vehicle group in the
acute phase and total and right hemisphere A9 lesion extent
(r = −0.580, p = 0.048, for total A9 lesion; r = −0.675, p = 0.016,
for right hemisphere A9 lesion; Table 1). We performed similar
analyses between lesion extent and the difference in the time
spent in LD box from pre to post-conditioning sessions in
the CPP (Table 2) but we found no significant correlations
(p> 0.05).
DISCUSSION
In the present work, we aimed at assessing the behavioral
consequences of LD administration in an animal model of
PD, with a focus on reward and impulsivity. Our model
was characterized by a significant anterior-posterior bilateral
dopaminergic degeneration in both A9 and A10 regions.
Importantly, the extent of our lesions presented some degree
of variability between experimental subjects. In addition to the
dopaminergic degeneration in A9 and A10 regions, we also
observed a significant reduction in DA content in their major
projection targets, dSTR and NAcc, respectively. As expected,
6-OHDA injections caused significant motor impairments in
skilled forelimb function in lesioned animals. In parallel, we
found that LD had a significant impact on impulsive-like
behavior. In the training phase of the VDS task we first observed
that 6-OHDA lesioned animals presented a significantly smaller
percentage of premature responses across sessions. This might
reflect differences in learning (and not in impulsivity), as
the curves converged at the end of the training period.
Indeed, at the 3 s phase of the VDS test day no differences
were observed. However, in the test day we observed, in
both acute and chronic phases, a significant increase in the
number of premature responses as the delay to response was
increasing. Additionally, our results showed that therapeutical
doses of LD further accentuated delay intolerance, as seen by
the increase of premature responses of LD-treated animals,
compared to their vehicle controls. In a previous report,
premature responses in this task were found to be sensitive to
the effects of impulsivity-inducing drugs (Leite-Almeida et al.,
2013). In the acute phase, the effects of LD administration on
increasing premature responses in the 12 s delay were seen
in sham animals, with 6-OHDA animals showing a trend for
increased premature responding. In turn, chronic LD treatments
significantly increased the number of premature responses in
6-OHDA animals, also in response to larger delays. We ruled
out the possible implication of increased motor activation caused
by LD on our results by quantifying the latency to feed, which
showed no differences between groups during either phase.
In the clinical context of human PD, the use of DAg has
been more strongly linked to the development of ICD than
LD (Driver-Dunckley et al., 2003; Weintraub et al., 2006).
Interestingly, there are cases of development of ICD only after
introduction of DAg in patients previously on LD monotherapy
(Klos et al., 2005). In line with this, previous experimental data
have shown that a widely used DAg, pramipexole, increases
impulsive responding in a striatum-lesioned model of PD, as
seen by a significant increase in probability discounting (Rokosik
and Napier, 2012). Based on this evidence, the interpretation
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TABLE 1 | Correlation analysis between A9/A10 lesion extent and premature responses during the 12 s delay trials of the variable delay-to-signal (VDS).
Lesion extension
6-OHDA + Vehicle
Premature responses 12 s A9 lesion A9 lesion right A9 lesion left A10 lesion A10 lesion right A10 lesion left
Acute phase
Pearson r −0.580 −0.675 −0.203 −0.395 −0.293 −0.340
p-value 0.048 0.016 0.528 0.204 0.355 0.280
Chronic phase
Pearson r −0.108 −0.495 0.311 0.150 −0.173 0.366
p-value 0.740 0.102 0.326 0.642 0.5912 0.241
6-OHDA + LD
Premature responses 12 s A9 lesion A9 lesion right A9 lesion left A10 lesion A10 lesion right A10 lesion left
Acute phase
Pearson r −0.041 −0.334 0.266 −0.323 −0.287 −0.216
p-value 0.894 0.265 0.379 0.281 0.341 0.480
Chronic phase
Pearson r −0.107 −0.177 −0.002 −0.442 −0.142 −0.534
p-value 0.728 0.564 0.995 0.131 0.643 0.060
Acute phase: 6-OHDA + vehicle, n = 12; 6-OHDA + LD, n = 13. Chronic phase: 6-OHDA + vehicle, n = 12; 6-OHDA + LD, n = 13. Highlighted values denote significant
correlation.
TABLE 2 | Correlation analysis between A9/A10 lesion extent and difference in time in levodopa (LD) box between pre and post-conditioning sessions in the conditioned
place preference (CPP).
Lesion extension
Difference in time LD box A9 lesion A9 lesion right A9 lesion left A10 lesion A10 lesion right A10 lesion left
Acute phase
Pearson r 0.199 −0.030 0.315 0.477 0.388 0.443
p-value 0.461 0.912 0.235 0.062 0.138 0.086
Chronic phase
Pearson r 0.281 0.303 0.182 0.442 0.469 0.314
p-value 0.311 0.272 0.517 0.099 0.079 0.254
Acute phase: 6-OHDA, n = 16. Chronic phase: 6-OHDA, n = 15.
of the LD effects we observed is not straightforward. However,
it has been shown that a combined use of LD and DAg
can increase the risk for the development of ICD when
compared to DAg monotherapy (Weintraub et al., 2010), and
that LD can increase delay intolerance—a construct that we
also analyzed with our task—in PD patients (Cools et al.,
2003). Although the exact mechanisms are currently not
understood, these observations together with our own results,
suggest that LD may play a role in the etiology of ICD.
More recently, a study reported that in an animal model
of PD with nigrostriatal degeneration, LD did not increase
motor or waiting impulsivity (Engeln et al., 2016). However,
it is important to highlight that unlike in the aforementioned
study, in which dopaminergic lesions were restricted to the
mesostriatal pathway, we employed here an animal model of
PD with both mesostriatal and mesocorticolimbic degeneration.
This difference could suggest that in PD a functional disruption
in both mesostriatal and mesocorticolimbic pathways might
be critical for the contribution of LD to the development of
impulsive behaviors.
A large body of evidence has established strong links between
disruptions in dopaminergic function and various forms of
impulsivity (Dalley and Roiser, 2012). However, impulsive
behaviors are not a typical manifestation of the parkinsonian
personality (Dagher and Robbins, 2009). This supports the
idea that although a parkinsonian condition is not sufficient
for the manifestation of ICD in PD, the interaction between
DRT and dysfunctional dopaminergic pathways might be one
of the factors behind the development of these behavioral
disturbances. Additionally, other factors such as impulsive
personality or a previous history of ICD or substance abuse
before disease onset, have also been shown to contribute
to an increased risk of ICD in PD (Ceravolo et al., 2009).
However, the effects of LD on impulsivity are not limited
to the PD condition. Indeed, we also observed in our study
that LD increased premature responding during the VDS task
in sham-lesioned animals. This result is in line with several
studies showing that the effects of dopaminergic stimulation with
pramipexole can significantly increase impulsive responding
in non-lesioned rats (Madden et al., 2010; Johnson et al.,
2011; Rokosik and Napier, 2012; Engeln et al., 2016), and
that LD can increase impulsivity in healthy humans (Pine
et al., 2010). Put together, the results of the studies discussed
above and ours, suggest that LD may thus hold a generalized
disruptive impact upon neural networks responsible for impulse
control. In the particular case of PD, such effects might
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interact in specific ways with a widespread functional disruption
in dopaminergic signaling and lead to ICD. However, the
exact mechanisms by which different classes of DRT might
affect each of the dopaminergic pathways that are differently
affected in PD, and later contribute to ICD, remain to be
elucidated.
Human evidence has also shown that a prolonged duration of
DRT treatment in PD patients is associated, among other factors,
with an increase in novelty-seeking scores, which can underlie
the development of impulsive behaviors that characterize ICD
(Bódi et al., 2009). However, our results from the VDS test,
and the comparison we have established between each individual
performance in the acute and chronic phase of the test did not
show a significant increase in premature responding as a result
of prolonged LD treatment.
In addition to the effects of LD on impulsivity, we investigated
the rewarding effects of LD in 6-OHDA-lesioned animals. In
our study, we observed that neither acute nor chronic LD
treatments were able to condition 6-OHDA-lesioned animals in
the CPP paradigm. Previous studies have shown that an acute LD
treatment holds rewarding properties in SNc-lesioned rodents
overexpressing α–synuclein (Engeln et al., 2013b); however, in
another study LD failed to condition a rat model of PD with
bilateral SNc/VTA model of PD (Zengin-Toktas et al., 2013).
Once more, the way dopaminergic function was differently
affected by the lesion strategies employed in each one of the
studies—SNc specific in the former and medial forebrain bundle
lesions in the later—could offer some explanation for the
observed discrepancies. Indeed, recent evidence showed that the
rewarding effects of several dopaminergic drugs were associated
with DA degeneration in the posterior, but not anterior, VTA
(Ouachikh et al., 2013, 2014), and that medial forebrain bundle
dopaminergic lesions increase sensitivity to the rewarding effects
of apomorphine, measured with CPP (Campbell et al., 2014).
Human studies have also shown that in PD patients reward
responsiveness was positively correlated with disease severity,
measured with DAT binding (Aarts et al., 2012). These results
seem to suggest that the rewarding effects of LD may depend on
the dopaminergic degeneration profile caused by PD-mimicking
lesions; however, more recent evidence reveals this may be
insufficient to fully explain LD-induced reward. For instance,
in relation to the study by Engeln et al. (2013b), in two
studies employing a similar lesion approach and higher LD
doses administered chronically, this drug failed to induce CPP
(Loiodice et al., 2017a,b).
Currently, the underlying mechanisms for the rewarding
effects of LD, are still poorly understood but they have been
proposed to stem from the repetitive overstimulation of the
brain reward system, which over time becomes hypersensitized
(Voon et al., 2017). Functional imaging studies performed in
PD patients with DDS/ICD support such hypothesis. On the
one hand, it has been shown that these patients display an
increased LD-induced DA release in the ventral striatum, which
was correlated with subjective LD craving (Evans et al., 2006).
On the other hand, additional studies have reported an increased
ventral striatal activation and DA release in response to reward-
related stimuli (Frosini et al., 2010; O’Sullivan et al., 2011).
These ventral striatal changes in dopaminergic signaling may
be related with the effects of LD on dopaminergic function.
Indeed, it has been proposed that as PD progresses, LD may
cause DA release in a more pulsatile fashion (Grace, 2008). This
continuous, pulsatile DA stimulation, mediated by high doses of
LD continuously administrated in PD patients, is reminiscent of
the physiological mechanisms that are believed to be responsible
for the psychostimulant effects of drugs of abuse (Wanat et al.,
2009), and could in turn mediate the rewarding effects of LD
administration (Voon et al., 2017). Moreover, it is becoming
increasingly acknowledged that the specific contribution of the
DA system in drug addiction varies according to different
classes of drugs of abuse (Pierce and Kumaresan, 2006). In
this sense, it is important to highlight that the specific effects
of LD on the complex neuronal networks that organize the
brain reward system, particularly in the parkinsonian context
and as disease progresses, are still poorly understood. Moreover,
and given that in human PD LD therapy is commonly given
in combination with other dopaminergic drugs, the rewarding
effects of LD might be caused or exacerbated by synergistic
effects with other DRT. In line with this, two studies showed
that chronic LD exposure accentuated the rewarding effects of
pramipexole administration, supporting the synergistic action
of both dopaminergic drugs in the development of medication-
induced conditioned responses in animals with PD lesions
(Loiodice et al., 2017a,b). Alternatively, or in combination
with these synergistic effects, individual vulnerability could
also contribute for the reinforcing effects of LD (O’Sullivan
et al., 2009). In this study, we looked for anatomical correlates
that could offer a possible explanation for higher individual
conditioned responses to LD in PD subjects. Our CPP analysis
did not show any association between increased time spend in LD
box and lesion extent in either A9 and A10, thus suggesting the
lack of a contribution of lesion extent for increased susceptibility
to any reinforcing effects of LD. However, a previous report
has already raised the point that individual predisposition for
the development of reward-seeking behaviors could help explain
exceedingly high levels of pramipexole self-administration in
PD rats (Engeln et al., 2013a). The sample size of these high
responders was too limited to draw strong conclusions so future
studies should further address this hypothesis.
The results of the present study add evidence to a growing
body of literature linking the use of DRT in PD and the
development of the behavioral complications that characterize
ICD/DDS. In particular, we present evidence that in a rat model
of PDwith bilateral A9 and A10 lesions, LD treatment can induce
the emergence of impulsivity-like behaviors, particularly after
extended exposure. Nowadays, we are becoming increasingly
aware of the complex dynamic changes that the progressive
nature of DA degeneration in PD imposes on reward and
impulse control brain networks, as well as the way DRT
act upon these networks. In the future, experimental studies
characterizing, in models of PD, the functional dynamics of DA
signaling in key brain regions implicated in reward and impulse
control, and following the long-term impact of DRT on these
same regions, will contribute to a better understanding of the
pathophysiological roots of DDS/ICD in PD.
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